Renal Treatment Centers Southeast, Lp is a medicare approved dialysis facility center in Donna, Texas and it has 21 dialysis stations. It is located in Hidalgo county at 1006 East Hwy 2, Donna, TX, 78537. You can reach out to the office of Renal Treatment Centers Southeast, Lp at (956) 461-2519. This dialysis clinic is managed and/or owned by Davita. Renal Treatment Centers Southeast, Lp has the following ownership type - Profit. It was first certified by medicare in April, 2018. The medicare id for this facility is 672843 and it accepts patients under medicare ESRD program.
| Name | Renal Treatment Centers Southeast, Lp |
|---|---|
| Location | 1006 East Hwy 2, Donna, Texas |
| No. of Dialysis Stations | 21 |
| Medicare ID | 672843 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 1006 East Hwy 2, Donna, Texas, 78537 | |
| (956) 461-2519 | |
| Not Available |
News Archive
Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.
Researchers at Huntsman Cancer Institute, in collaboration with a worldwide group of physicians and scientists, have discovered a remarkable treatment for a rare, yet debilitating, skin condition.
Since 2003, breast augmentation utilizing stem cells from autologous fat has been developed enabling silicon-free breast reconstruction following cancer surgery. Till now though, it was unclear whether this might reactivate the cancer again. However, University of Pittsburgh researchers led by Prof. Albert Donnenberg have now demonstrated that stem cell-enriched autologous fat is safe even in the presence of inactive tumor cells.
Since the Centers for Disease Control and Prevention (CDC) released revised recommendations for opt-out HIV testing in 2006, there has been significant debate around the barriers to widespread implementation of the recommendations.
Antisense Therapeutics Limited is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose).
› Verified 9 days ago
| NPI Number | 1902353543 |
| Organization Name | Donna Dialysis |
| Doing Business As | Renal Treatment Centers Southeast Lp |
| Address | 1006 E Interstate Highway 2 Donna, Texas, 78537 |
| Phone Number | (956) 854-2099 |
News Archive
Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.
Researchers at Huntsman Cancer Institute, in collaboration with a worldwide group of physicians and scientists, have discovered a remarkable treatment for a rare, yet debilitating, skin condition.
Since 2003, breast augmentation utilizing stem cells from autologous fat has been developed enabling silicon-free breast reconstruction following cancer surgery. Till now though, it was unclear whether this might reactivate the cancer again. However, University of Pittsburgh researchers led by Prof. Albert Donnenberg have now demonstrated that stem cell-enriched autologous fat is safe even in the presence of inactive tumor cells.
Since the Centers for Disease Control and Prevention (CDC) released revised recommendations for opt-out HIV testing in 2006, there has been significant debate around the barriers to widespread implementation of the recommendations.
Antisense Therapeutics Limited is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose).
› Verified 9 days ago